Rhodamine 123 Requires Carrier-Mediated Influx for Its Activity as a P-Glycoprotein Substrate in Caco-2 Cells
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Purpose. The purpose of this work was to elucidate transport pathways of the P-glycoprotein (P-gp) substrates rhodamine 123 (R123) and doxorubicin across Caco-2 cells.
Methods. Experiments were designed to identify saturable and nonsaturable transport processes and transport barriers for R123 and doxorubicin transport across Caco-2 cells. Confocal laser scanning microscopy (CLSM) imaged R123 transport under normal conditions and in the presence of the P-gp inhibitor, GW918 (used to abolish P-gp-mediated efflux activity).
Results. R123 secretory P app (P app,BA) showed concentration dependence, whereas R123 absorptive P app (P app,AB) did not. Inhibition of P-gp efflux revealed that P-gp-mediated efflux had no effect on R123 or doxorubicin P app,AB, but enhanced R123 and doxorubicin P app,BA. In calcium-free medium, R123 P app,AB increased 15-fold, indicating intercellular junctions are a barrier to R123 absorption. CLSM of R123 fluorescence during absorptive transport under normal conditions and in the presence of GW918 was identical, and was limited to paracellular space, confirming that P-gp is not a barrier to R123 absorption. CLSM revealed that R123 fluorescence during secretory transport under normal conditions and in the presence of GW918 was localized intracellularly and in paracellular space. R123 and doxorubicin uptake across Caco-2 cells basolateral membrane was saturable.
Conclusions. R123 absorptive transport occurs primarily by paracellular route, whereas R123 secretory transport involves influx across BL membrane mediated solely by a saturable process followed by apically directed efflux via P-gp. Doxorubicin utilizes similar transport pathways to cross Caco-2 cells.
- M. F. Fromm. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 38:69-74 (2000).
- J. A. Silverman. Multidrug-resistance transporters. Pharm. Biotechnol. 12:353-386 (1999).
- S. Hsing, Z. Gatmaitan, and I. M. Arias. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 102:879-885 (1992).
- F. Thiebaut, T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84:7735-7738 (1987).
- P. Borst, A. H. Schinkel, J. J. Smit, E. Wagenaar, L. Van Deemter, A. J. Smith, E. W. Eijdems, F. Baas, and G. J. Zaman. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol. Ther. 60:289-299 (1993).
- P. Borst and A. H. Schinkel. What have we learnt thus far from mice with disrupted P-glycoprotein genes? Eur. J. Cancer 32A:985-990 (1996).
- B. L. Lum and M. P. Gosland. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol. Oncol. Clin. North Am. 9:319-336 (1995).
- R. B. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J. Wood, D. M. Roden, and G. R. Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294 (1998).
- G. Y. Kwei, R. F. Alvaro, Q. Chen, H. J. Jenkins, C. E. Hop, C. A. Keohane, V. T. Ly, J. R. Strauss, R. W. Wang, Z. Wang, T. R. Pippert, and D. R. Umbenhauer. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab. Dispos. 27:581-587 (1999).
- A. Sparreboom, J. van Asperen, U. Mayer, A. H. Schinkel, J. W. Smit, D. K. Meijer, P. Borst, W. J. Nooijen, J. H. Beijnen, and O. van Tellingen. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 94:2031-2035 (1997).
- W. L. Chiou, S. M. Chung, and T. C. Wu. Commentary: Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm. Res. 17:901-903 (2000).
- K. Arimori and M. Nakano. Drug exsorption from blood into the gastrointestinal tract. Pharm. Res. 15:371-376 (1998).
- J. van Asperen, O. van Tellingen, and J. H. Beijnen. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab. Dispos. 28:264-267 (2000).
- U. Mayer, E. Wagenaar, J. H. Beijnen, J. W. Smit, D. K. Meijer, J. van Asperen, P. Borst, and A. H. Schinkel. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br. J. Pharmacol. 119:1038-1044 (1996).
- B. Greiner, M. Eichelbaum, P. Fritz, H. P. Kreichgauer, O. von Richter, J. Zundler, and H. K. Kroemer. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104:147-153 (1999).
- H. Diddens, V. Gekeler, M. Neumann, and D. Niethammer. Characterization of actinomycin-D-resistant CHO cell lines exhibiting a multidrug-resistance phenotype and amplified DNA sequences. Int. J. Cancer 40:635-642 (1987).
- J. S. Lee, K. Paull, M. Alvarez, C. Hose, A. Monks, M. Grever, A. T. Fojo, and S. E. Bates. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46:627-638 (1994).
- R. Yumoto, T. Murakami, Y. Nakamoto, R. Hasegawa, J. Nagai, and M. Takano. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J. Pharmacol. Exp. Ther. 289:149-155 (1999).
- M. Takano, R. Hasegawa, T. Fukuda, R. Yumoto, J. Nagai, and T. Murakami. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur. J. Pharmacol. 358:289-294 (1998).
- M. D. Perloff, L. L. von Moltke, E. Stormer, R. I. Shader, and D. J. Greenblatt. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br. J. Pharmacol. 134:1601-1608 (2001).
- J. M. Dintaman and J. A. Silverman. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res. 16:1550-1556 (1999).
- S. Tansan, Y. Koc, H. Aydin, G. Urbano, and R. McCaffrey. Augmentation of vincristine cytotoxicity by megestrol acetate. Cancer Chemother. Pharmacol. 39:333-340 (1997).
- C. W. Cho, Y. Liu, X. Yan, T. Henthorn, and K. Y. Ng. Carrier-mediated uptake of rhodamine 123: implications on its use for MDR research. Biochem. Biophys. Res. Commun. 279:124-130 (2000).
- R. Masereeuw, M. M. Moons, and F. G. Russel. Rhodamine 123 accumulates extensively in the isolated perfused rat kidney and is secreted by the organic cation system. Eur. J. Pharmacol. 321:315-323 (1997).
- I. C. van der Sandt, M. C. Blom-Roosemalen, A. G. de Boer, and D. D. Breimer. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur. J. Pharm. Sci. 11:207-214 (2000).
- P. Schmiedlin-Ren, K. E. Thummel, J. M. Fisher, M. F. Paine, K. S. Lown, and P. B. Watkins. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxy-vitamin D3. Mol. Pharmacol. 51:741-754 (1997).
- K. Lee and D. R. Thakker. Saturable transport of H2-antagonists ranitidine and famotidine across Caco-2 cell monolayers. J. Pharm. Sci. 88:680-687 (1999).
- L. S. Gan, P. H. Hsyu, J. F. Pritchard, and D. Thakker. Mechanism of intestinal absorption of ranitidine and ondansetron: transport across Caco-2 cell monolayers. Pharm. Res. 10:1722-1725 (1993).
- F. Hyafil, C. Vergely, P. Du Vignaud, and T. Grand-Perret. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:4595-4602 (1993).
- P. F. Augustijns, T. P. Bradshaw, L. S. Gan, R. W. Hendren, and D. R. Thakker. Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 197:360-365 (1993).
- J. Hunter, M. A. Jepson, T. Tsuruo, N. L. Simmons, and B. H. Hirst. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. 268:14991-14997 (1993).
- A. B. Shapiro and V. Ling. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur. J. Biochem. 250:130-137 (1997).
- M. A. Hurni, A. B. Noach, M. C. Blom-Roosemalen, A. G. de Boer, J. F. Nagelkerke, and D. D. Breimer. Permeability enhancement in Caco-2 cell monolayers by sodium salicylate and sodium taurodihydrofusidate: assessment of effect-reversibility and imaging of transepithelial transport routes by confocal laser scanning microscopy. J. Pharmacol. Exp. Ther. 267:942-950 (1993).
- T. J. Lampidis, C. Castello, A. del Giglio, B. C. Pressman, P. Viallet, K. W. Trevorrow, G. K. Valet, H. Tapiero, and N. Savaraj. Relevance of the chemical charge of rhodamine dyes to multiple drug resistance. Biochem. Pharmacol. 38:4267-4271 (1989).
- F. Ingels, S. Deferme, E. Destexhe, M. Oth, G. Van den Mooter, and P. Augustijns. Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. Int. J. Pharm. 232:183-192 (2002).
- L. P. Rivory, K. M. Avent, and S. M. Pond. Effects of lipophilicity and protein binding on the hepatocellular uptake and hepatic disposition of two anthracyclines, doxorubicin and iododoxorubicin. Cancer Chemother. Pharmacol. 38:439-445 (1996).
- G. A. Altenberg, C. G. Vanoye, J. K. Horton, and L. Reuss. Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane. Proc. Natl. Acad. Sci. USA 91:4654-4657 (1994).
- G. van Meer and K. Simons. The function of tight junctions in maintaining differences in lipid composition between the apical and the basolateral cell surface domains of MDCK cells. EMBO J. 5:1455-1464 (1986).
- A. Collett, N. B. Higgs, E. Sims, M. Rowland, and G. Warhurst. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J. Pharmacol. Exp. Ther. 288:171-178 (1999).
- M. D. Troutman and D. R. Thakker. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture. Models of intestinal epithelium. Pharm. Res. >20:1210-1224 (2003).
- Rhodamine 123 Requires Carrier-Mediated Influx for Its Activity as a P-Glycoprotein Substrate in Caco-2 Cells
Volume 20, Issue 8 , pp 1192-1199
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- rhodamine 123
- intestinal absorption
- intestinal secretion
- Industry Sectors